-

MindWalk CTO Dr. Dirk Van Hyfte to Join Fireside Chat at AI Drug Discovery & Development Summit 2025

AUSTIN, Texas--(BUSINESS WIRE)--MindWalk Holdings Corp.™ (“MindWalk,” “Company,” “we” or “us”) (Nasdaq: HYFT), a Bio-Native AI company, today announced that Dr. Dirk Van Hyfte, Chief Technology Officer, will participate in a fireside chat during the Biology Session at the AI Drug Discovery & Development Summit 2025, taking place on November 20, 2025, from 12:15 PM to 12:45 PM.

"His work exemplifies how scientific depth and data-driven design can come together to advance precision discovery.”

Share

The AI Drug Discovery & Development Summit is a premier event that brings together industry leaders, researchers, and innovators to explore how artificial intelligence is reshaping drug discovery pipelines and accelerating therapeutic development. Dr. Van Hyfte will share insights on how MindWalk’s HYFT®-powered LensAi™ platform is unlocking new opportunities to index, connect, and continuously update biological knowledge at scale—redefining how the industry approaches discovery and development.

“We’re pleased to see Dr. Van Hyfte representing MindWalk’s vision for Bio-Native AI and Deep Data internationally,” said Dr. Jennifer Bath, CEO of MindWalk. “His work exemplifies how scientific depth and data-driven design can come together to advance precision discovery.”

For more information on the event, visit the official website: AI Drug Discovery & Development Summit 2025

About MindWalk
MindWalk is a Bio-Native AI company transforming drug discovery and development. Powered by patented HYFT® technology and the LensAI™ platform, MindWalk unifies sequence, structure, function, and literature into a single computational language and closes the loop with an integrated, full-stack wet lab. The platform supports rapid epitope mapping, de novo molecular design, in silico vaccine exploration, and population-scale biologics analytics that help turn insights into validated candidates at speed.

Source: MindWalk Holdings Corp.

Contacts

Investor Contact
Louie Toma, CPA, CFA
Managing Director, CoreIR
investors@mindwalkAI.com

Industry:

MindWalk Holdings Corp.

NASDAQ:HYFT
Release Versions
EnglishFrench
$Cashtags
$HYFT
Hashtags
#AI
#BIONATIVEAI
#DrugDiscovery
#TechBio
#llm

Contacts

Investor Contact
Louie Toma, CPA, CFA
Managing Director, CoreIR
investors@mindwalkAI.com

Social Media Profiles
Linkedin
MindWalk Holdings on X
More News From MindWalk Holdings Corp.

MindWalk Brings OpenFold3 into Production in Minutes with AMD Inference Microservices on Vultr Kubernetes Engine

AUSTIN, Texas--(BUSINESS WIRE)--MindWalk Holdings Corp. ("MindWalk") (NASDAQ: HYFT), a Bio-Native AI company, today announced results from a production deployment of the open-source OpenFold3 structure prediction model, run with engineering partners AMD and Vultr on Vultr Kubernetes Engine and Vultr Cloud GPU powered by AMD Instinct™ MI325X GPUs and delivered through AMD Inference Microservices (AIM). It also served as an independent validation of AIM for OpenFold3 in a production life-sciences...

MindWalk Reports 21% Revenue Growth and Gross Margin Expansion to 59% in Fiscal First Quarter 2027

AUSTIN, Texas--(BUSINESS WIRE)--MindWalk Holdings Corp. ("MindWalk") (NASDAQ: HYFT), a Bio-Native AI company, today reported financial results for its fiscal 2027 first quarter ended July 31, 2026. The quarter marked the commercial launch of ReefIQ™, MindWalk's data platform, and the start of its shift toward recurring, platform-based revenue. Revenue increased 21.3% year over year to $3.8 million. Gross profit increased 47.1% to $2.2 million; gross margin expanded to 58.6% from 48.3%. Net cash...

MindWalk Lands Binding Commitment for US$30 Million Unsecured Credit Facility to Fund Biologics Programs and Commercial Expansion

AUSTIN, Texas--(BUSINESS WIRE)--MindWalk Holdings Corp. ("MindWalk") (NASDAQ: HYFT), a Bio-Native AI company, today announced that it has entered into a binding commitment with Sanabil (Cayman) for a senior unsecured revolving credit facility of up to US$30 million. The facility is intended to support MindWalk’s biologics programs, commercial expansion, working capital, and general corporate purposes. The facility carries a fixed annual interest rate of 7.00%, accruing only on amounts drawn, an...
Back to Newsroom